LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC. Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned. Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-2

Kiri Karl Morgensternile, Berlin

http://tartu.ester.ee/record=b1779113~S1*es

Kiri tundmatule

Wolf, Friedrich August, 1759-1824, klassikaline filoloog, prof. HallesRaamatute tellimin

4 kirja Karl Morgensternile

http://tartu.ester.ee/record=b1743684~S1*es

Kiri Karl Morgensternile, Berlin

http://tartu.ester.ee/record=b1782820~S1*es

Friedr. Aug. Wolf's ... vermischte Schriften und Aufsätze in lateinischer und deutscher Sprache

Friedrich August Wol

Homeri Odyssea Et Batrachomyomachia : In Usum Scholarum Et Praelectionum / [Frid. Aug. Wolfius]

HOMERI ODYSSEA ET BATRACHOMYOMACHIA : IN USUM SCHOLARUM ET PRAELECTIONUM / [FRID. AUG. WOLFIUS] Homeri Odyssea Et Batrachomyomachia : In Usum Scholarum Et Praelectionum / [Frid. Aug. Wolfius] (1) Einband (1) Titelblatt (7) Lectori S. D. Frid. Aug. Wolfius. (9) Homeri Odyssea (41) Batrachomyomachia (505) Fotodokumentation (525

Platonis Dialogorum Delectus ... Ex Recensione Et Cum Latina Interpretatione Frid. Aug. Wolfii. In Usum Gymnasiorum

PLATONIS DIALOGORUM DELECTUS ... EX RECENSIONE ET CUM LATINA INTERPRETATIONE FRID. AUG. WOLFII. IN USUM GYMNASIORUM Platonis Dialogorum Delectus ... Ex Recensione Et Cum Latina Interpretatione Frid. Aug. Wolfii. In Usum Gymnasiorum (1) Einband (1) Titelseite (3) Titelblatt (7) Platonos Euthyphron (9) Platonos Apologia Sokratus (43) Platonos Kriton (91) Platonis Euthyphro (117) Platonis Apologia Socratis (151) Platonis Crito (201) Fotodokumentation (233

Homeri Carmina / Secundum recensionem Wolfii Cum Praefatione Gothofredi Hermanni

HOMERI CARMINA / SECUNDUM RECENSIONEM WOLFII CUM PRAEFATIONE GOTHOFREDI HERMANNI Homeri Carmina / Secundum recensionem Wolfii Cum Praefatione Gothofredi Hermanni Ilias (Vol. 1